- Home
- RGLS vs AXR Comparison
RGLS vs AXR Comparison
Compare RGLS & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- AXR
- Stock Information
- Founded
- RGLS 2007
- AXR 1961
- Country
- RGLS United States
- AXR United States
- Employees
- RGLS N/A
- AXR N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- AXR Homebuilding
- Sector
- RGLS Health Care
- AXR Real Estate
- Exchange
- RGLS Nasdaq
- AXR Nasdaq
- Market Cap
- RGLS 102.8M
- AXR 114.5M
- IPO Year
- RGLS 2012
- AXR N/A
- Fundamental
- Price
- RGLS $1.58
- AXR $21.49
- Analyst Decision
- RGLS Strong Buy
- AXR
- Analyst Count
- RGLS 6
- AXR 0
- Target Price
- RGLS $10.33
- AXR N/A
- AVG Volume (30 Days)
- RGLS 289.5K
- AXR 9.9K
- Earning Date
- RGLS 08-08-2024
- AXR 10-11-2024
- Dividend Yield
- RGLS N/A
- AXR N/A
- EPS Growth
- RGLS N/A
- AXR N/A
- EPS
- RGLS N/A
- AXR 1.25
- Revenue
- RGLS N/A
- AXR $51,369,000.00
- Revenue This Year
- RGLS N/A
- AXR N/A
- Revenue Next Year
- RGLS N/A
- AXR N/A
- P/E Ratio
- RGLS N/A
- AXR $17.44
- Revenue Growth
- RGLS N/A
- AXR 5.53
- 52 Week Low
- RGLS $1.08
- AXR $15.38
- 52 Week High
- RGLS $3.79
- AXR $26.77
- Technical
- Relative Strength Index (RSI)
- RGLS 46.25
- AXR 43.37
- Support Level
- RGLS $1.47
- AXR $20.81
- Resistance Level
- RGLS $1.72
- AXR $22.05
- Average True Range (ATR)
- RGLS 0.12
- AXR 0.84
- MACD
- RGLS -0.01
- AXR -0.12
- Stochastic Oscillator
- RGLS 38.00
- AXR 42.45
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve the obtaining of approvals and the sale of both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.